Seroprevalence of viral hepatitis B, C and E in TB patients from the Republic of Moldova
Vol. 4 No. 1 (2023), Research articles
Vol. 4 No. 1 (2023)

Seroprevalence of viral hepatitis B, C and E in TB patients from the Republic of Moldova

Research articles
https://doi.org/10.38045/ohrm.2023.1.07
Published January 1, 2023
Octavian SAJIN
National Agency for Public Health, Chisinau, Republic of Moldova
Constantin SPINU
National Agency for Public Health, Chisinau, Republic of Moldova
Maria ISAC
National Agency for Public Health, Chisinau, Republic of Moldova
Nina IZIUMOV
National Agency for Public Health, Chisinau, Republic of Moldova
Aliona CHERNIAVSKA
National Agency for Public Health, Chisinau, Republic of Moldova
Alexandru BUGA
Municipal Clinical Hospital of Pneumology, Chisinau, Republic of Moldova
Igor CIOBANU
Nicolae TestemițanuState University of Medicine and Pharmacy, Chisinau, Republic of Moldova
pdf

Keywords

seroprevalence
laboratory investigations
viral hepatitis B, C and E
TB patients

How to Cite

SAJIN, O., SPINU, C., ISAC, M., IZIUMOV, N., CHERNIAVSKA, A., BUGA, A. and CIOBANU, I. (2023) “Seroprevalence of viral hepatitis B, C and E in TB patients from the Republic of Moldova”, One Health & Risk Management , 4(1), pp. 59-64. doi: 10.38045/ohrm.2023.1.07.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Introduction. For the first time, in the Republic of Moldova, there was established the seroprevalence of viral hepatitis B, C and E markers in patients with tuberculosis depending on gender, age and geographical areas.

Material and methods. 200 blood samples were collected from patients with tuberculosis and tested by the immuno-fermentative method for presence of viral hepatitis B, C and E markers.

Results. Following the investigations, it was established that the seroprevalence of the anti-HEV Ig marker in patients with tuberculosis is 12.0±2.3%. The seroprevalence of viral hepatitis B marker HBsAg in patients with tuberculosis was 13.5±2.4%, and that of viral hepatitis C anti-HCV – 9.0±2.0%. The study of investigations results for the presence of nominated markers depending on the geographical areas showed a significant statistically difference in the seroprevalence of the anti-HEV IgG marker in TB patients in the Central area of the country compared to the Southern area(p<0.05).

Conclusions. Patients with tuberculosis have a higher risk of developing viral hepatitis B, C and E, mainly affecting people aged 40-49 and > 60 years, including males.

https://doi.org/10.38045/ohrm.2023.1.07
pdf

|Views: 237| |pdf Downloads: 144|


pdf
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2023 Octavian Sajin

Downloads

Download data is not yet available.

<!--LiveInternet counter--><script type="text/javascript">
document.write('<a href="//www.liveinternet.ru/click" '+
'target="_blank"><img src="//counter.yadro.ru/hit?t20.4;r'+
escape(document.referrer)+((typeof(screen)=='undefined')?'':
';s'+screen.width+'*'+screen.height+'*'+(screen.colorDepth?
screen.colorDepth:screen.pixelDepth))+';u'+escape(document.URL)+
';h'+escape(document.title.substring(0,150))+';'+Math.random()+
'" alt="" title="LiveInternet: показано число просмотров за 24'+
' часа, посетителей за 24 часа и за сегодня" '+
'border="0" width="88" height="31"><\/a>')
</script><!--/LiveInternet-->

<!--LiveInternet counter--><script type="text/javascript">
document.write('<a href="//www.liveinternet.ru/click" '+
'target="_blank"><img src="//counter.yadro.ru/hit?t20.4;r'+
escape(document.referrer)+((typeof(screen)=='undefined')?'':
';s'+screen.width+'*'+screen.height+'*'+(screen.colorDepth?
screen.colorDepth:screen.pixelDepth))+';u'+escape(document.URL)+
';h'+escape(document.title.substring(0,150))+';'+Math.random()+
'" alt="" title="LiveInternet: показано число просмотров за 24'+
' часа, посетителей за 24 часа и за сегодня" '+
'border="0" width="88" height="31"><\/a>')
</script><!--/LiveInternet-->

ANNOUNCEMENT

Starting from July 1, 2025, the article processing fee will be 20 EUR (or the equivalent in MDL at the official exchange rate of the National Bank of Moldova). The publication fee for an accepted article will be 150 EUR (or the equivalent in MDL).

Details here:

Processing Fee
A processing fee of 20 EUR (or the equivalent in MDL) will be charged for articles accepted for scientific review by the editorial committee of the One Health and Risk Management journal.
Note: This fee will only be charged if your article has been technically reviewed and accepted.

Publication Fee
Starting from 01.07.2025, a fee of 150 EUR (or the equivalent in MDL) will be charged for articles accepted for publication.
Additionally, authors will bear the cost of English language editing/translation services if the manuscript requires intervention. The fee is 5 EUR (or the equivalent in MDL) per page edited/translated.
The total cost for English editing/translation services will be communicated by the Editorial Board after the manuscript is accepted for publication.

Payment Details:
Payments should be made in MDL to the bank account opened in the name of the Biosafety and Biosecurity Association of the Republic of Moldova.
The invoice will be issued by the end of the month in which the payment was made.

Organization: Biosafety and Biosecurity Association of the Republic of Moldova
Address: 5C A. Cozmescu Street
Fiscal Code: 1017620004120
Bank Code (SWIFT): AGRNMD2X451
IBAN: MD34AG000000022513622370